| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The Journal of Immunology, Vol 128, Issue 5 2009-2012, Copyright © 1982 by American Association of Immunologists
ARTICLES |
AU Krettli and Z Brener
A dissociation between antibodies involved in the diagnosis of Trypanosoma cruzi infections and those participating in resistance against this parasite is reported. Mice immunized with different T. cruzi antigens (frozen-thawed culture forms, glutaraldehyde-fixed blood trypomastigotes, "metabolic antigens" from blood parasites, and surface glycoprotein from epimastigotes) present only antibodies detected by conventional immunofluorescence tests (IFA) using fixed parasites. However, mice chronically infected with T. cruzi harbor both reactive IFA antibodies and antibodies against living blood forms (ALBA) detectable by complement-mediated lysis (CML). Challenge of the various groups of animals with virulent T. cruzi show that only mice presenting ALBA are strongly resistant. In addition, the antibody lytic activity is lost in mice parasitologically cured after specific treatment. Those findings strongly suggest that ALBA are good markers for monitoring protection in experiments of vaccination against T. cruzi. They also support our previous suggestion that the search for antibodies against living blood forms, detected mainly by CML, is an important element in establishing a reliable criterion of cure in human Chagas' disease.
This article has been cited by other articles:
|
|
 |
|
  H. R. Martins, L. M. Figueiredo, J. C. O. Valamiel-Silva, C. M. Carneiro, G. L. L. Machado-Coelho, D. M. Vitelli-Avelar, M. T. Bahia, O. A. Martins-Filho, A. M. Macedo, and M. Lana Persistence of PCR-positive tissue in benznidazole-treated mice with negative blood parasitological and serological tests in dual infections with Trypanosoma cruzi stocks from different genotypes J. Antimicrob. Chemother., June 1, 2008; 61(6): 1319 - 1327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. R. Martins, R. M. Silva, H. M. S. Valadares, M. J. O. Toledo, V. M. Veloso, D. M. Vitelli-Avelar, C. M. Carneiro, G. L. L. Machado-Coelho, M. T. Bahia, O. A. Martins-Filho, et al. Impact of Dual Infections on Chemotherapeutic Efficacy in BALB/c Mice Infected with Major Genotypes of Trypanosoma cruzi Antimicrob. Agents Chemother., September 1, 2007; 51(9): 3282 - 3289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Koga, S. Hamano, H. Kuwata, K. Atarashi, M. Ogawa, H. Hisaeda, M. Yamamoto, S. Akira, K. Himeno, M. Matsumoto, et al. TLR-Dependent Induction of IFN-beta Mediates Host Defense against Trypanosoma cruzi J. Immunol., November 15, 2006; 177(10): 7059 - 7066. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. S. F. Meira, L. M. C. Galvao, E. D. Gontijo, G. L. L. Machado-Coelho, K. A. Norris, and E. Chiari Use of the Trypanosoma cruzi Recombinant Complement Regulatory Protein To Evaluate Therapeutic Efficacy following Treatment of Chronic Chagasic Patients J. Clin. Microbiol., February 1, 2004; 42(2): 707 - 712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. S. F. Meira, L. M. C. Galvao, E. D. Gontijo, G. L. L. Machado-Coelho, K. A. Norris, and E. Chiari Trypanosoma cruzi Recombinant Complement Regulatory Protein: a Novel Antigen for Use in an Enzyme-Linked Immunosorbent Assay for Diagnosis of Chagas' Disease J. Clin. Microbiol., October 1, 2002; 40(10): 3735 - 3740. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. A. Martins-Filho, S. M. Eloi-Santos, A. T. Carvalho, R. C. Oliveira, A. Rassi, A. O. Luquetti, G. G. Rassi, and Z. Brener Double-Blind Study To Evaluate Flow Cytometry Analysis of Anti-Live Trypomastigote Antibodies for Monitoring Treatment Efficacy in Cases of Human Chagas' Disease Clin. Vaccine Immunol., September 1, 2002; 9(5): 1107 - 1113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Schnapp, C. S. Eickhoff, D. Sizemore, R. Curtiss III, and D. F. Hoft Cruzipain Induces Both Mucosal and Systemic Protection against Trypanosoma cruzi in Mice Infect. Immun., September 1, 2002; 70(9): 5065 - 5074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Muller, G. Kohler, H. Mossmann, G. A. Schaub, G. Alber, J. P. Di Santo, F. Brombacher, and C. Holscher IL-12-Independent IFN-{gamma} Production by T Cells in Experimental Chagas' Disease Is Mediated by IL-18 J. Immunol., September 15, 2001; 167(6): 3346 - 3353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. D. Cordeiro, O. A. Martins-Filho, M. O. Da Costa Rocha, S. J. Adad, R. Correa-Oliveira, and A. J. Romanha Anti-Trypanosoma cruzi Immunoglobulin G1 Can Be a Useful Tool for Diagnosis and Prognosis of Human Chagas' Disease Clin. Vaccine Immunol., January 1, 2001; 8(1): 112 - 118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sepulveda, M. Hontebeyrie, P. Liegeard, A. Mascilli, and K. A. Norris DNA-Based Immunization with Trypanosoma cruzi Complement Regulatory Protein Elicits Complement Lytic Antibodies and Confers Protection against Trypanosoma cruzi Infection Infect. Immun., September 1, 2000; 68(9): 4986 - 4991. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. F. Hoft, A. R. Schnapp, C. S. Eickhoff, and S. T. Roodman Involvement of CD4+ Th1 Cells in Systemic Immunity Protective against Primary and Secondary Challenges with Trypanosoma cruzi Infect. Immun., January 1, 2000; 68(1): 197 - 204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Wizel, N. Garg, and R. L. Tarleton Vaccination with Trypomastigote Surface Antigen 1-Encoding Plasmid DNA Confers Protection against Lethal Trypanosoma cruzi Infection Infect. Immun., November 1, 1998; 66(11): 5073 - 5081. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Norris Stable Transfection of Trypanosoma cruzi Epimastigotes with the Trypomastigote-Specific Complement Regulatory Protein cDNA Confers Complement Resistance Infect. Immun., June 1, 1998; 66(6): 2460 - 2465. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
